261 related articles for article (PubMed ID: 17168705)
21. 2-Chloro-2'-deoxyadenosine (2CdA) biochemical aspects of antileukemic efficacy.
Fabianowska-Majewska K; Wyczechowska D
Acta Pol Pharm; 1996; 53(4):231-9. PubMed ID: 9415193
[TBL] [Abstract][Full Text] [Related]
22. In vitro efficacy of forodesine and nelarabine (ara-G) in pediatric leukemia.
Homminga I; Zwaan CM; Manz CY; Parker C; Bantia S; Smits WK; Higginbotham F; Pieters R; Meijerink JP
Blood; 2011 Aug; 118(8):2184-90. PubMed ID: 21730354
[TBL] [Abstract][Full Text] [Related]
23. Therapy of chronic lymphocytic leukaemia with purine nucleoside analogues: facts and controversies.
Robak T
Drugs Aging; 2005; 22(12):983-1012. PubMed ID: 16363884
[TBL] [Abstract][Full Text] [Related]
24. Forodesine, an inhibitor of purine nucleoside phosphorylase, induces apoptosis in chronic lymphocytic leukemia cells.
Balakrishnan K; Nimmanapalli R; Ravandi F; Keating MJ; Gandhi V
Blood; 2006 Oct; 108(7):2392-8. PubMed ID: 16778146
[TBL] [Abstract][Full Text] [Related]
25. New nucleoside analogs for patients with hematological malignancies.
Robak T
Expert Opin Investig Drugs; 2011 Mar; 20(3):343-59. PubMed ID: 21320002
[TBL] [Abstract][Full Text] [Related]
26. Adverse and beneficial immunological effects of purine nucleoside analogues.
Dighiero G
Hematol Cell Ther; 1996 Dec; 38 Suppl 2():S75-81. PubMed ID: 9137960
[TBL] [Abstract][Full Text] [Related]
27. Phosphorylation of deoxycytidine kinase on Ser-74: impact on kinetic properties and nucleoside analog activation in cancer cells.
Amsailale R; Van Den Neste E; Arts A; Starczewska E; Bontemps F; Smal C
Biochem Pharmacol; 2012 Jul; 84(1):43-51. PubMed ID: 22490700
[TBL] [Abstract][Full Text] [Related]
28. A comparison of the transportability, and its role in cytotoxicity, of clofarabine, cladribine, and fludarabine by recombinant human nucleoside transporters produced in three model expression systems.
King KM; Damaraju VL; Vickers MF; Yao SY; Lang T; Tackaberry TE; Mowles DA; Ng AM; Young JD; Cass CE
Mol Pharmacol; 2006 Jan; 69(1):346-53. PubMed ID: 16234483
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of the combination of nelarabine and fludarabine in leukemias: clinical response, pharmacokinetics, and pharmacodynamics in leukemia cells.
Gandhi V; Plunkett W; Weller S; Du M; Ayres M; Rodriguez CO; Ramakrishna P; Rosner GL; Hodge JP; O'Brien S; Keating MJ
J Clin Oncol; 2001 Apr; 19(8):2142-52. PubMed ID: 11304766
[TBL] [Abstract][Full Text] [Related]
30. Purine nucleoside phosphorylase inhibitor BCX-1777 (Immucillin-H)--a novel potent and orally active immunosuppressive agent.
Bantia S; Miller PJ; Parker CD; Ananth SL; Horn LL; Kilpatrick JM; Morris PE; Hutchison TL; Montgomery JA; Sandhu JS
Int Immunopharmacol; 2001 Jun; 1(6):1199-210. PubMed ID: 11407314
[TBL] [Abstract][Full Text] [Related]
31. Second malignancies as a consequence of nucleoside analog therapy for chronic lymphoid leukemias.
Cheson BD; Vena DA; Barrett J; Freidlin B
J Clin Oncol; 1999 Aug; 17(8):2454-60. PubMed ID: 10561309
[TBL] [Abstract][Full Text] [Related]
32. Selective toxicity of purine nucleosides to human leukaemic cells.
Piga A; Ganeshaguru K; Green ES; Sheridan B; Hoffbrand AV
Adv Exp Med Biol; 1989; 253B():291-8. PubMed ID: 2514591
[TBL] [Abstract][Full Text] [Related]
33. The role of nucleoside analogues in the treatment of chronic lymphocytic leukemia-lessons learned from prospective randomized trials.
Robak T
Leuk Lymphoma; 2002 Mar; 43(3):537-48. PubMed ID: 12002757
[TBL] [Abstract][Full Text] [Related]
34. Old and new insights into the mechanisms of action of two nucleoside analogs active in lymphoid malignancies: fludarabine and cladribine (review).
Van den Neste E; Cardoen S; Offner F; Bontemps F
Int J Oncol; 2005 Oct; 27(4):1113-24. PubMed ID: 16142330
[TBL] [Abstract][Full Text] [Related]
35. Pharmacology and mechanism of action of forodesine, a T-cell targeted agent.
Gandhi V; Balakrishnan K
Semin Oncol; 2007 Dec; 34(6 Suppl 5):S8-12. PubMed ID: 18086347
[TBL] [Abstract][Full Text] [Related]
36. Down-regulation of deoxycytidine kinase in human leukemic cell lines resistant to cladribine and clofarabine and increased ribonucleotide reductase activity contributes to fludarabine resistance.
Månsson E; Flordal E; Liliemark J; Spasokoukotskaja T; Elford H; Lagercrantz S; Eriksson S; Albertioni F
Biochem Pharmacol; 2003 Jan; 65(2):237-47. PubMed ID: 12504799
[TBL] [Abstract][Full Text] [Related]
37. Comparison of cytotoxicity of 2-chloro- 2'-arabino-fluoro-2'-deoxyadenosine (clofarabine) with cladribine in mononuclear cells from patients with acute myeloid and chronic lymphocytic leukemia.
Lindemalm S; Liliemark J; Gruber A; Eriksson S; Karlsson MO; Wang Y; Albertioni F
Haematologica; 2003 Mar; 88(3):324-32. PubMed ID: 12651272
[TBL] [Abstract][Full Text] [Related]
38. Deoxycoformycin (pentostatin): clinical pharmacology, role in the chemotherapy of cancer, and use in other diseases.
Spiers AS
Haematologia (Budap); 1996; 27(2):55-84. PubMed ID: 14651224
[TBL] [Abstract][Full Text] [Related]
39. Purine nucleoside antimetabolites in development for the treatment of cancer.
Parker WB; Secrist JA; Waud WR
Curr Opin Investig Drugs; 2004 Jun; 5(6):592-6. PubMed ID: 15242246
[TBL] [Abstract][Full Text] [Related]
40. A proof-of-principle pharmacokinetic, pharmacodynamic, and clinical study with purine nucleoside phosphorylase inhibitor immucillin-H (BCX-1777, forodesine).
Gandhi V; Kilpatrick JM; Plunkett W; Ayres M; Harman L; Du M; Bantia S; Davisson J; Wierda WG; Faderl S; Kantarjian H; Thomas D
Blood; 2005 Dec; 106(13):4253-60. PubMed ID: 16131572
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
